Malignant peripheral nerve sheath tumor (MPNST) is an aggressive malignancy with considerable biological variability, a variable and often lethal clinical course, and limited response to current therapeutic approaches. A major impediment to more effective disease management has been a lack of available prognostic or predictive biomarkers.
STATEMENT OF TRANSLATIONAL RELEVANCE
Malignant peripheral nerve sheath tumor (MPNST) is an aggressive malignancy with considerable biological variability, a variable and often lethal clinical course, and limited response to current therapeutic approaches. A major impediment to more effective disease management has been a lack of available prognostic or predictive biomarkers.
Through initial identification of several survival-associated copy-number alterations, followed by confirmatory assays and a comprehensive multivariate analysis, our present study demonstrates that CDK4 gain/amplification and increased FOXM1 protein expression are significant independent predictors for poor survival in MPNST patients. If confirmed in additional prospective studies, these biomarkers may provide clinically useful information for managing patients with this aggressive malignancy. Interestingly,
INTRODUCTION
Malignant peripheral nerve sheath tumors (MPNSTs) are highly aggressive and frequently lethal Schwann cell-derived neoplasms associated with poor survival (1) (2) (3) (4) (5) .
Roughly half of MPNSTs develop sporadically and the other half arise in the setting of neurofibromatosis type 1 (NF1). The five year survival rate for NF1-associated MPNST patients is reportedly half of that for sporadic cases (21% vs. 42%) (5) . However, other studies suggest that a diagnosis of NF1 does not affect survival (6) . Clinicopathologic factors, such as tumor grade and anatomic site reportedly influence MPNST patient outcome, although the clinical course remains highly variable and difficult to predict in individual patients.
Traditional cytogenetic studies have reported that MPNSTs have remarkably complex karyotypes with a wide spectrum of chromosomal alterations including translocations, duplications, and numerical gains and losses, making it difficult to discern which of these alterations are biologically relevant (7) (8) (9) . Unfortunately, no single alteration has consistently proven to be diagnostically or prognostically useful across multiple studies. For example, alterations on chromosome 17 (where the NF1 gene is located) are expected, given that MPNSTs are highly over-represented among NF1 cancers (11) (12) (13) . To date, a similar approach applied to MPNSTs has been limited to few studies with either less comprehensive or lower resolution array platforms (~1 Mb) (14) (15) (16) . In the present study, we have analyzed a larger cohort of MPNSTs utilizing both Affymetrix and Nimblegen array-based comparative genome hybridization platforms (0.25-2.5 kb of resolution with whole genome coverage) in order to identify recurrent DNA copy-number alterations (CNAs) that are associated with reduced patient survival, independent of traditional clinical and pathological parameters in patients with this extremely heterogeneous tumor. The results from this study provide a short list of candidate genes with CNAs which may prove clinically useful as prognostic biomarkers for patients with MPNST.
MATERIALS AND METHODS

Patients and specimens
A cohort of 38 patients with histologically-confirmed MPNST was included in this study for microarray analysis. Among the 38 patients, 23 (60%) individuals carried a previous diagnosis of Neurofibromatosis Type I (NF1) and 15 (40%) were sporadic cases. At the time of last follow-up, 14 (37%) cases had documented metastases while 16 (42%) had no evidence of metastatic disease. Recurrence data was unavailable for 8 of the cases.
These same specimens were previously utilized for gene expression profiling (17) . For biomarker validation studies, another independent set of 121 formalin-fixed paraffin embedded MPNST tumors represented in a tissue microarray (TMA) was utilized; 87 of these patients had clinical annotation and follow up data (18) . Of these 87 annotated cases 25 (29%) were NF1-associated and 62 (71%) were sporadic MPNSTs. A total of 68 primary, 12 locally recurrent, and 7 metastatic tumors were represented. The majority of the tumors (78/87) were high grade and 9/87 were classified as low grade.
Supplemental Table T2 provides additional data regarding the validation set. All tissue specimens and clinical data from these patients were collected and utilized in accordance with IRB-approved protocols.
Array-based comparative genome hybridization (aCGH)
The Affymetrix Genome-wide 500K SNP Mapping array set was employed to detect genomic alterations in the set of 38 MPNSTs. For aCGH analysis, relative copy-number values of the MPNSTs were generated using a reference set of 37 non-malignant DNA samples derived from 22 males and 15 females. To identify meaningful CNAs, two DNA copy-number analysis tools, Partek Genomics Suite (PARTEK, www.partek.com) and Copy-Number Analyzer for GeneChip (CNAG, www.genome.umin.jp) (19) tumor and germline DNAs were available, using a dual-color high-density NimbleGen 135K aCGH platform (see Supplemental Text for details).
Quantitative real-time PCR (qPCR)
SYBR Green chemistry was utilized in qPCR assays; qPCR primer sequences are listed in Supplemental Table T3 . The qPCR was performed in 10-μl reactions containing 10 ng of cDNA or genomic DNA and gene-specific primers each at 200 nM of final concentration, as previously described (20) , on the ABI 7900HT system with the following program: 50 °C for 2 min, 95 °C for 10 min, and 40 cycles of 95 °C for 15 sec, 56 °C for 30 sec, and 72 °C for 30 sec. All sets of primers yielded a single peak in dissociation curve analysis and had an efficiency of greater than 0.9.
Immunohistochemistry (IHC)
Fresh tissue microarray (TMA) sections were obtained from the Washington University/Siteman Cancer Center Tissue Procurement Core Facility and IHC was performed using the streptavidin-biotin-peroxidase complex technique as described previously (21) Evaluation of each core on the TMA was made independently by two pathologists (L.S., A.P.), and the final score for each tumor was derived from the average score of replicate cores on the arrays (see Supplemental Text). CDK4 TMA immunohistochemistry was also performed, but was not interpretable due to poor staining quality of this antibody reagent on the TMA spots.
Research. 
Fluorescence in situ hybridization (FISH)
FISH was performed on TMA slides as previously described (22, 23) . Freshly cut slides were subjected to dual-color hybridization with the following probe pairings: centromere enumerating probe 12 (CEP12)/CDK4 (12q14.1), CEP17/HER2 (ERBB2; 17q21.1), and CEP8/MYC (8q24.21), respectively. Five of the probes were obtained commercially and were labeled with SpectrumGreen (CEP8, CEP12, and CEP17) or SpectrumOrange (MYC and ERBB2) fluorochromes (Vysis, Downers Grove, IL). The CDK4 locus was targeted with a locally developed probe, utilizing the RP11-571M6 human BAC clone as previously published (24) 
Statistical analysis
Each of the minimally overlapping genomic regions was tested for association with clinical variables, for which the Kaplan-Meier model was used for survival analysis.
Differential expression of candidate genes was detected between patients with and without CNAs where positive correlations with survival were seen using the MannWhitney U test. Survival probability was first estimated using the Breslow test (univariate Cox regression) for each of the genomic and relevant clinical variables, and then the significant predictors in univariate models were entered into multivariate models. The stepwise selection method was utilized to build the most significant models.
The cutoff P value was set as 0.05. All computations were performed in SAS (v9. 
RESULTS
Characterization of MPNST genomic alterations
As shown by high resolution aCGH ( Fig. 1) and further quantified by calculation of the "breakpoint index" (a surrogate measure of genomic instability calculated based upon the total number of independently amplified and deleted genomic segments identified in a tumor based on aCGH analysis, see ref. 13 ), MPNSTs demonstrate a highly complex and disrupted genome. MPNST genomes had higher overall complexity (mean "breakpoint index"=346) compared to similarly characterized genomes of other tumor types: leukemia (mean=88) (25) , ovarian cancer (median=95) (13) , and pilocytic astrocytoma (mean=111) (20) . The indices were, however, similar to lymphoma (mean=374) (26) . The percentage of the total genome affected by CNAs was also calculated to assess genome complexity of individual tumors. This ranged widely from 0.2% to 97% (median 34%) among the 38 MPNSTs (Fig. 1C ). This observation no doubt reflects the pathological diversity of tumors characterized in this cohort, although a direct association between reduced survival time and overall high genome complexity (defined here as 34% of the genome affected by CNA) did not quite reach statistical significance ( Fig. 2A, p=0 .071).
Many of the genomic loci associated with recurrent copy number alterations harbor genes previously implicated in MPNST biology and were observed with frequencies comparable to those reported in previous studies (14) (Supplemental Table   T4 ). For example, 19 of 38 (50%) cases had deletion at the NF1 locus. Interestingly, however, this event was independent of clinical diagnosis as 13 (27) , PTPRD at 9p23-24.1 (47% of cases) (28) and PTEN at 10q23.31 (34% cases). Although it is likely that NF1-associated and sporadic MPNSTs arise in the context of different genetic backgrounds, we found that none of these nor any other loci identified in this analysis was present with statistical significance between NF1 associated and sporadic MPNSTs.
Identification of survival-associated genomic alterations
Minimally overlapping regions of genome alteration (1564 copy-number gains and 252 copy-number losses) identified using two alternate segment calling algorithms were correlated with clinical variables. Each genome region evaluated contained at least one annotated gene and recurred in greater than 10% of 38 tumors. A detection frequency of 10% (4 tumors) was chosen as a minimum cut-off to provide sufficient statistical power given the sample size and recognizing the already extreme diversity of this tumor type. Using either Mann-Whitney U test or Chi-square test, no significant association was observed between these regions and clinical variables such as age, gender, tumor status (i.e., primary or recurrent), anatomic location and grade, metastasis, recurrence, or NF1 association. Using the Kaplan-Meier model however, 36 minimally overlapping regions with copy-number gains demonstrated significant associations with decreased survival times (Supplemental Table T5 ). No regions with copy-number losses were statistically associated with patient survival. When ranked by both frequency and p-value, the most significant region of copy number gain was a 173kb minimally overlapping region at 12p12.1 that includes only a portion of the SOX5 gene (Fig. 2B) . This region demonstrated copy-number gains in 13 tumors, but with variability in the size of the locus affected (Fig. 3A) . Three other genomic regions associated with survival were also identified (Fig. 2C-2E) , where differential mRNA expression was seen in at least one overlapping gene for each of the regions, based on previously published expression profiling data of the same tumors (Table 1 ) (17) . The sizes of these three regions were 265kb at 12p13.31, 551kb at 12p13.33, and 420kb at 12q14.1, and included the entire coding sequence of NOL1/MLF2 (9 cases; 25%), FOXM1/FKBP4 (11 cases; 31%), and CDK4/TSPAN31 (9 cases; 25%), respectively ( Fig. 3B-3D ). In comparison, the 8q24.21 locus harboring MYC, a gene frequently amplified in neuroectodermal tumors, was also frequently amplified in 13 (34%) MPNSTs (Fig. 3E ) and was associated with a trend toward decreased survival (p>0.05). As described below, this association reached statistical significance on subsequent confirmation experiments that evaluated MYC protein expression (Fig. 2G) .
Confirmation of copy-number alterations associated with survival
To confirm results obtained from aCGH data sets, qPCR was performed to quantify DNA copy number for 7 specific candidate genes using the same 38 MPNST DNAs employed for aCGH analysis. DNA qPCR results confirmed associations between decreased survival and DNA copy-number gains for all 7 genes (Table 1) . Using the same MPNST RNAs from our previously reported gene expression microarray study (17) , qRT-PCR analysis confirmed differential expression for 5 of the 7 genes (NOL1,
MLF2, FOXM1, FKBP4, and CDK4), whereas SOX5 and TSPAN31 showed no differential expression ( Table 1 ). Given that only a portion of the SOX5 gene was involved in the amplified region, we questioned whether this amplification reflected a qualitative rearrangement of the locus, rather than SOX5 amplification. However, sequencing of RNAs from tumors that exhibited SOX5 amplification using both 3' and 5' RACE (rapid amplification of cDNA ends) failed to identify a novel fusion gene transcript in these tumors (data not shown).
We also employed an independent cohort of 121 patients tumors (87 with clinical follow-up) to construct a tissue microarray and evaluate gene amplification and protein expression of several candidate genes (CDK4, FOXM1 and SOX5) that were identified and confirmed by the genomic approaches described above. For comparison, we also examined several other previously reported biomarkers of survival (ERBB2, MYC and TP53) in this same cohort. Using Kaplan-Meier survival analysis, CDK4 amplification in 12 of 79 (15%) cases (scored as both true gene amplification and high-level polysomies/gains by FISH analysis) and increased protein expression of FOXM1 and MYC were statistically associated with significantly shorter overall survival in this cohort (Fig. 2G-2I and Fig. 4 ). In contrast, MYC and ERBB2 gene amplification as well as TP53 (Fig. 2J ) and SOX5 protein immunoreactivity were not associated with overall survival.
Finally, a multivariate analysis was carried out to determine whether any of the genomic biomarkers identified could serve as independent predictors for survival (Table   2 ). Among all genomic and clinical variables examined, only 4 CNA regions (representatively named as CDK4, FOXM1, NOL1, and SOX5) and anatomic site ( 2F) showed significant associations with survival time by univariate regression analysis in the 38 MPNSTs. In addition, CDK4 gene amplification by FISH analysis, FOXM1 and MYC protein expression, tumor type (i.e., primary, recurrent, or metastatic) (Fig. 2K) and tumor grade (Fig. 2L ) also demonstrated statistically significant association with overall survival. In multivariate analysis, however, the most significant survival predictor was CDK4 copy-number gain by aCGH in the 38 patient cohort and corresponding CDK4 gene amplification by FISH in the 87 patient cohort. Tumor anatomic site in the 38 patient cohort, and high FOXM1 protein expression and tumor type in the 87 patient cohort were also independently significant in multivariate analyses.
DISCUSSION
MPNST is an aggressive malignancy with considerable biological variability and limited response to current therapeutic approaches. This phenomenon is well demonstrated by the clinical heterogeneity of patient outcome in the current study, with overall survival ranging from less than a month to over 13 years. A major impediment to more effective disease management has been a lack of available prognostic or predictive biomarkers.
While other sarcomas exhibit characteristic translocations that lead to signature fusion transcripts (29) , a definitive set of clinically relevant genomic alterations has been difficult to identify for MPNST, likely due to the large number of gross structural genomic aberrations identified in individual tumors.
Our current study provides one of the first global, high-resolution genomic views of MPNST with independent validation of several biologically relevant genes. Not surprisingly, the overall level of genomic complexity is higher than previously observed 
RNA expression levels correlated with survival, we did not observe a similar relationship at the genome level, as determined by either FISH or aCGH. This suggests that mechanisms of increased expression at the transcriptional level may be more important for this particular gene. These repeated observations underscore the need for a comprehensive evaluation of all candidate biomarkers at the genome, transcriptome, and protein levels in independent sample sets, particularly as they are being considered as prognostic tools.
For example, in the recent literature, p53 expression has been proposed as an important predictor of survival time in MPNST patients (30, 31) . Our data, however, did not confirm this finding at the level of protein expression, gene expression, or genome deletion. Although 50% of MPNSTs had deletions at the TP53 locus in our present study, differential mRNA expression between TP53 deleted and non-deleted tumors was not seen (p>0.05) and TP53 deletion itself did not stratify MPNST patients by survival. Furthermore, in the second cohort of 87 MPNSTs, p53 immunoreactivity was not statistically associated with survival time. One reason for this discrepancy between our current study and previous studies could reflect the presence of p53 substitution mutations that would obviously not be detected by aCGH but that could affect protein expression and stability. However, the analytical and interpretive techniques applied to immunohistochemistry in the current study were similar to those of previous reports and as such, this discrepancy is more difficult to explain. In contrast, we did identify recurrent copy number gains involving loci at 12p13.31 and 12p13.33 that were associated with survival on univariate analyses. Although these two regions did not remain statistically significant in our primary cohort of 38 MPNST patients by 
multivariate analysis, we were able to subsequently demonstrate concurrent mRNA and protein overexpression of FOXM1 in this region. In a second larger cohort of 87
MPNSTs, FOXM1 over-expression by IHC was associated with poor survival, a significance which was retained on multivariate analysis. FOXM1 is a transcription factor that is only expressed in proliferating cells and has critical functions in tumor development and progression (32, 33) . Expression has been associated with enhanced invasion and metastasis in pancreatic and prostate cancers (32, 34) . Increased expression of FOXM1 also correlates with increased tumorigenicity of cultured glioma cells and in human glioblastomas, its expression levels are inversely correlated with patient survival (35) . Our current data suggests that increased FOXM1 protein expression is a significant predictor of poor survival in MPNST patients. MPNSTs analyzed in this study. To our knowledge, our study is the first to provide specific evidence for a significant association between CDK4 amplification and poor patient survival in MPNSTs. Interestingly, a previous report has demonstrated that the multi-kinase inhibitor sorafenib can inhibit MPNST growth, in part through hypophosphorylation of pRB at CDK4-specific sites (40), suggesting the potential of CDK4 as a therapeutic target and also as a potential predictive biomarker of response to sorafenib therapy.
In conclusion, CDK4 gain/amplification and increased FOXM1 protein expression were the most significant independent predictors for poor survival in MPNST patients after accounting for well established clinicopathologic prognostic variables in MPNSTs.
If confirmed in prospective studies, these prognostic and potentially predictive biomarkers may provide clinically useful information for managing patients with this aggressive malignancy. Not significant n/a n/a ERBB1 Not significant No n/a n/a Not significant n/a MYC Not significant Yes n/a n/a Not significant Significant TP53 Not significant No n/a n/a n/a Not significant
